Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients

Dec 09, 2019
  • Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell disease and a pattern of not seeking care despite potentially life-threatening symptoms1
     
  • Patients reported on average more than 5 vaso-occlusive crises (VOCs) per year with serious impact on their quality of life (QoL), including emotional well-being and daily life, as well as ability to work and complete education1,2
     
  • Sickle Cell World Assessment Survey (SWAY), one of world’s largest sickle cell disease surveys, supported by international steering committee of medical experts and patient advocates

Basel, December 9, 2019 — “We see sickle cell as a painful disease, but too often we don't translate how that pain affects the lives of our patients – can they go to school, can they work, can they enjoy their families? These are things many of us take for granted,” said Ifeyinwa Osunkwo, MD, MPH, Founder and Director, Sickle Cell Disease Enterprise, Levine Cancer Institute, Atrium Health and co-chair of the SWAY Steering Committee. “Perhaps health care providers don’t always see the impact of sickle cell disease in that light. Now, with the results of this worldwide sickle cell survey, we have a clearer picture of the toll it takes on millions of people around the world.”

The Sickle Cell World Assessment Survey (SWAY) collected insights from more than 2,100 patients and 300 health care providers to evaluate the impact of the disease on patients and families and help inform the management of this life-long condition. Results were presented at the 2019 American Society of Hematology (ASH) Annual Meeting.

Results showed substantially higher numbers of vaso-occlusive crises (VOCs) than current published data suggesting VOCs are highly underreported and many are experienced at home:

  • On average, patients experienced more than 5 VOCs each year,1 and
  • More than 90% of patients surveyed experienced at least one VOC in the past 12 months1
  • Of the more than 11,000 VOCs reported, nearly one quarter were managed at home1

Considered the clinical hallmark of the disease, VOCs are unpredictable, severe events associated with life-threatening complications.3 They are the main reason why sickle cell disease patients go to the emergency room or are admitted to the hospital.4 However, despite the serious risks, nearly one quarter of respondents said they avoid seeking medical assistance, citing previous poor hospital experiences (39%), perception that health care providers do not understand sickle cell disease (26%), or their pain is too severe to leave home (19%).1 

“Hearing first-hand from those living with sickle cell disease is incredibly important to shaping how we address their concerns,” said John James, OBE, Chief Executive, UK Sickle Cell Society. “With these new insights, we can improve how we manage this serious disease and help improve quality of life for these individuals.”

Results also showed that sickle cell disease has a high impact on patients’ ability to work and complete their education:

  • Over half said they believe their income would be higher if they didn’t have the disease2
  • More than half (53%) report they have reduced hours at work because of their disease2
  • More than 50% reported sickle cell disease has had a high impact on their achievement at school2

“At Novartis, we are pursuing collaborative research efforts to broaden our understanding of sickle cell disease beyond just its devastating physical symptoms,” said Andrew Cavey, Global Program Head, Benign Hematology, Novartis. “On behalf of a coalition of involved organizations and individuals, we were pleased to share compelling new data from one of the world’s largest sickle cell disease surveys that uncover the real-world impact of this condition on those touched by it.”
            

Members of the SWAY Steering Committee of clinical experts and patient advocates include:

  • Alecia Nero, MD, University of Texas Southwestern Medical Center, Dallas, Texas, USA
  • Baba Inusa, MD, Paediatric Haematology, Evelina Children's Hospital, Guy's and St Thomas' Hospital, London, UK
  • Beverley Francis-Gibson, MA, Sickle Cell Disease Association of America, Baltimore, Maryland, USA
  • Biree Andemariam, MD, New England Sickle Cell Institute, Division of Hematology-Oncology, Neag Comprehensive Cancer Center, UCONN Health, University of Connecticut, Farmington, Connecticut, USA
  • Cassandra Trimnell, Sickle Cell 101, San Jose, California, USA
  • Caterina Minniti, MD, Montefiore Health System, Albert Einstein College of Medicine, New York, USA
  • Fuad El-Rassi, MD, Department of Hematology and Medical Oncology, Emory University School of Medicine and Georgia Comprehensive Sickle Cell Center at Grady Health System, Atlanta, Georgia, USA
  • Erfan Nur, PhD, MD, Department of Clinical Hematology, Academic Medical Center, Amsterdam, The Netherlands
  • Ify Osunkwo, MD, MPH, Sickle Cell Disease Enterprise at The Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA
  • Jastaniah Wasil, MD, College of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia
  • Jean-Benoit Arlet, MD, Hôpital Européen Georges-Pompidou, Paris, France
  • John James, OBE, Sickle Cell Society, London, UK
  • Mariane de Montalembert, MD, Hôpital universitaire Necker-Enfants maladies, Paris, France
  • Marimilia Pita, MD, Brazilian Society of Oncology, Pediatric Oncology, Brazil
  • Miguel Abboud, MD, American University of Beirut Medical Center, Beirut, Lebanon
  • Raffaella Colombatti, MD, PhD, Clinica di Oncoematologia Pediatrica, Dipartimento della Salute della Donna e del Bambino Azienda Ospedaliera, Università di Padova, Padova, Italy
  • Suman Jain, MD, Thalassemia And Sickle Cell Society, Hyderabad, India

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartisnews and follow @NovartisCancer at https://twitter.com/NovartisCancer
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]

References
1. Osunkwo I, Andemariam B, Inusa B, et al. Management Strategies and Satisfaction Levels in Patients With Sickle Cell Disease: Interim Results From the International Sickle Cell World Assessment Survey (SWAY). Poster presented at: The American Society of Hematology Annual Meeting; December 7-10, 2019; Orlando, FL.
2. Osunkwo I, Andemariam B, Inusa B, et al. Impact of Sickle Cell Disease Symptoms on Patients’ Daily Lives: Interim Results From the International Sickle Cell World Assessment Survey (SWAY). Poster presented at: The American Society of Hematology Annual Meeting; December 7-10, 2019; Orlando, FL.
3. Steinberg M. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030.
4. Gutsaeva D, Parkerson J, Yerigenahally S, et al. Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. 2011;117(2):727-735.


# # #

Novartis Media Relations
E-mail: [email protected]

Antonio Ligi
Novartis Global Media Relations
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
[email protected]

 

Eric Althoff
Novartis US External Communications
+ 1 646 438 4335
[email protected]
Michael Billings
Novartis Hematology Communications
+1 862 778 8656 (direct)
+1 201 400 1854 (mobile)
[email protected]
  

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]

Central North America 
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Pierre-Michel Bringer+41 61 324 1065Cory Twining+1 862 778 3258
Thomas Hungerbuehler+41 61 324 8425  
Isabella Zinck+41 61 324 7188